background
number
antivir
therapi
evolv
may
effect
administ
treat
respiratori
viral
diseas
therapi
often
limit
efficaci
sever
side
effect
therefor
great
interest
develop
new
efficaci
safe
antivir
compound
eg
base
identif
compound
herbal
origin
hypothesi
sinc
aqueou
extract
alo
arborescen
mill
show
antivir
activ
virus
caus
infect
upper
respiratori
tract
vitro
hypothesis
product
contain
biaron
c
could
antivir
activ
studi
design
antivir
activ
bioaron
c
herbal
medicin
product
consist
aqueou
extract
alo
arborescen
mill
vitamin
c
aronia
melanocarpa
elliot
succu
ad
excipi
test
vitro
broad
panel
virus
involv
upper
respiratori
tract
infect
method
studi
includ
human
adenoviru
sever
rna
virus
perform
either
plaqu
reduct
assay
test
detect
viruscaus
cytopath
effect
result
studi
demonstr
impress
activ
bioaron
c
member
orthomyxovirida
influenza
influenza
b
virus
replic
analys
influenza
viru
strain
well
replic
two
analys
influenza
b
virus
strain
yamagat
beiy
significantli
reduc
addit
bioaron
c
infect
cell
cultur
contrast
antivir
activ
bioaron
c
rna
virus
show
heterogen
pattern
bioaron
c
inhibit
replic
human
rhinoviru
coxsackieviru
virus
belong
famili
picornavirida
repres
nonenvelop
rna
virus
vitro
infect
respiratori
syncyti
viru
parainfluenza
viru
belong
paramyxovirida
poorli
block
test
substanc
antivir
activ
bioaron
c
detect
adenoviru
nonenvelop
dna
viru
conclus
result
repres
first
proof
select
antivir
activ
bioaron
c
influenza
virus
creat
basi
analys
type
molecular
mechan
antivir
activ
herbal
medicin
number
antivir
therapi
effect
administ
treat
respiratori
viral
diseas
thu
provid
physician
rang
compound
includ
amantadin
hay
et
al
neuraminidas
inhibitor
calfe
hayden
nucleosid
analogu
fyfe
et
al
hruska
et
al
therapi
compound
often
limit
efficaci
hand
sideeffect
system
toxic
may
limit
applic
http
elsevi
gmbh
right
reserv
particularli
paediatr
geriatr
immunocompromis
patient
bacon
et
al
cassadi
whitley
englund
et
al
hayden
et
al
janai
et
al
reusser
result
great
interest
develop
new
efficaci
safe
antivir
agent
plant
extract
wide
use
tradit
medicin
declercq
due
antimicrobi
antivir
activ
interestingli
enough
speci
studi
show
signific
antivir
efficaci
vitro
che
although
studi
systemat
investig
activ
broad
panel
virus
still
remain
done
summerfield
et
al
describ
activ
acanthospermum
hispidum
dc
asteracea
anim
pathogen
herp
virus
pseudorabiesviru
prv
bovin
herpesviru
show
et
al
antivir
activ
extract
eleutherococcu
senticosu
maxim
araliacea
human
rhinoviru
hrv
human
respiratori
syncyti
viru
rsv
influenza
viru
discuss
rnaviru
specif
reactiv
micha
et
al
investig
influenc
standardis
extract
pelargonium
sidoid
dc
geraniacea
treatment
acut
bronchiti
replic
panel
respiratori
virus
author
abl
show
concentr
interf
replic
season
influenza
viru
strain
rsv
human
coronaviru
parainfluenza
viru
coxsacki
viru
affect
replic
highli
pathogen
avian
influenza
viru
adenoviru
hrv
antivir
potenti
also
demonstr
combin
gentian
root
primula
flower
elder
flower
sorrel
herb
verbena
herb
reduc
vitro
spread
influenza
rsv
parainfluenza
type
viru
para
glatthaar
et
al
present
studi
antivir
effect
herbal
medicin
use
prevent
treatment
upper
respiratori
tract
infect
consist
alo
arborescen
mill
xanthorrhoeacea
vitamin
c
excipi
aronia
melanocarpa
elliot
rosacea
succu
name
bioaron
c
investig
arborescen
use
treatment
upper
respiratori
tract
infect
central
eastern
european
countri
mani
decad
recent
preclin
studi
bioaron
c
show
vitro
clear
dosedepend
antivir
activ
human
rhinoviru
hrv
et
al
addit
clinic
studi
show
antiinflammatori
antivir
activ
contribut
therapeut
efficaci
viral
infect
upper
respiratori
tract
bastian
et
al
last
publish
data
bioaron
c
refer
observ
studi
involv
children
characteris
suscept
upper
respiratori
tract
infect
result
studi
suggest
bioaron
c
success
use
treatment
viral
infect
adjuv
antibiot
therapi
shorten
durat
infect
caus
milder
cours
infect
follow
studi
focus
antivir
activ
bioaron
c
virus
caus
infect
upper
respiratori
tract
get
detail
inform
specif
plant
extract
get
hint
possibl
mode
action
therefor
antivir
activ
bioaron
c
test
dna
viru
adenoviru
adeno
well
broad
panel
envelop
nonenvelop
rna
virus
nonenvelop
virus
respons
major
acut
respiratori
infect
children
adult
coxsackieviru
type
tend
infect
skin
mucou
membran
caus
herpangina
acut
haemorrhag
conjunct
handfootandmouth
hfm
diseas
includ
analys
among
envelop
rna
virus
chose
parainfluenzaviru
para
rsv
associ
bronchiol
pneumonia
main
focu
studi
set
reactiv
test
substanc
differ
strain
influenza
virus
belong
either
type
influenza
virus
influenza
type
b
influenza
virus
influenza
b
yamagat
influenza
b
beiy
bioaron
c
syrup
commerci
avail
herbal
medicin
product
aqueou
extract
arborescen
plu
vitamin
c
phytopharm
sa
now
miasto
nad
poland
excipi
sucros
concentr
chokeberri
juic
melanocarpa
sodium
benzoat
purifi
water
use
alo
extract
arborescen
leav
key
ingredi
syrup
contain
mg
extract
mg
vitamin
c
per
ml
present
investig
origin
product
bioaron
c
investig
without
sugar
prepar
ingredi
except
arborescen
sugar
serv
assay
neg
solvent
control
medicin
product
base
arborescen
aqueou
extract
wide
use
poland
russia
ukrain
focu
upper
respiratori
tract
infect
children
lack
appetit
longlast
ill
bastian
et
al
european
pharmacopoeia
hmpc
monograph
differ
alo
speci
especi
alo
ferox
mill
alo
barbadensi
mill
describ
lax
effect
base
high
content
hydroxyanthraquinon
howev
arborescen
characteris
low
anthranoid
content
therefor
without
lax
effect
phytopharm
sa
person
commun
natur
habitat
arborescen
mountain
region
southern
africa
arborescen
also
grown
sourc
materi
medicin
cosmet
food
use
variou
countri
china
israel
itali
japan
poland
green
hous
ukrain
crimea
peninsula
jambor
plant
use
studi
cultiv
harvest
greenhous
plantat
phytopharm
sa
poland
aloenin
analyt
marker
specifi
bioaron
c
alo
extractum
fluidum
activ
substanc
medicin
product
reproduc
manufactur
process
confirm
check
aolenin
level
everi
batch
activ
substanc
medicin
product
phytopharm
sa
analyt
procedur
valid
accord
ich
guidanc
rang
deriv
linear
studi
assay
method
cover
concentr
mg
aloenin
per
ml
alo
extractum
fluidum
wherea
averag
content
marker
ml
aloenin
content
bioaron
c
vari
ml
averag
valu
ml
ident
bioaron
c
confirm
detect
aloenin
chromatogram
profil
bioaron
c
togeth
aloenin
present
fig
aloenin
b
bioaron
c
determin
vitamin
c
bioaron
c
conduct
direct
redox
titrat
method
acid
condit
iodin
solut
c
moll
one
millilitr
moll
iodin
solut
correspond
mg
vitamin
c
molal
titrant
determin
direct
titrat
mean
moll
sodium
thiosulph
solut
vitro
assay
test
substanc
dilut
describ
respect
cell
cultur
media
control
serv
solvent
control
without
activ
compon
arborescen
prepar
condit
verifi
test
system
ribavirin
sigmaaldrich
germani
includ
assay
posit
control
known
antivir
activ
rna
virus
hruska
et
al
amantadin
sigmaaldrich
germani
cyclic
amin
activ
eg
earli
step
influenza
replic
also
use
posit
control
richman
et
al
efficaci
refer
substanc
confirm
antivir
assay
human
rhinoviru
b
subtyp
hrv
obtain
institut
virolog
friedrichschillerunivers
jena
germani
human
influenza
viru
strain
influenza
chile
viru
flua
influenza
flua
well
influenza
b
strain
influenza
b
flub
yamagat
influenza
b
flub
beiy
season
viru
strain
togeth
respiratori
syncyti
viru
strain
long
rsv
parainfluenza
type
viru
para
coxsackieviru
subtyp
adenoviru
c
subtyp
adeno
viru
strain
obtain
former
depart
medic
virolog
epidemiolog
viru
diseas
hygien
institut
univers
germani
rsv
para
adeno
propag
human
epitheli
cell
hrv
hela
cell
buffalogreenmonkey
bgm
cell
hanksearl
minim
essenti
medium
mem
contain
vv
foetal
calf
serum
mm
mgcl
mm
l
glutamin
uml
penicillin
mgml
streptomycin
flua
flua
well
flub
yamagat
flub
beiy
grown
madindarbi
caninekidney
mdck
cell
serumfre
mem
contain
trypsin
mm
lglutamin
uml
penicillin
mgml
streptomycin
order
determin
viru
titr
respect
cell
incub
serial
dilut
serumfre
viru
stock
solut
h
remov
viru
inoculum
cell
cultur
overlaid
respect
virusspecif
medium
contain
agaros
analys
plaqu
plaqueform
unit
pfu
cytopathogen
effect
cpe
perform
day
later
respect
viru
titr
calcul
pfu
per
millilitr
method
cavallisforza
spearmankaerb
method
mean
tissu
cultur
infecti
dose
tcid
per
millilitr
adeno
plaquereduct
assay
assay
cpe
perform
mdck
bgm
helacel
cultur
use
standard
procedur
detect
infecti
particl
viru
plaqu
cpe
quantifi
employ
optic
evalu
system
elispot
reader
aid
diagnostika
gmbh
germani
tabl
interpret
refer
colour
figur
legend
reader
refer
web
version
articl
quantif
adeno
antigen
enzym
immunoassay
merlin
diagnostika
gmbh
bornheimhersel
germani
use
analys
vitro
cytotox
bioaron
c
perform
physiolog
activ
cell
enzymat
assay
mttassay
mosmann
capabl
quantifi
activ
mitochondri
enzym
activ
divid
cell
show
direct
correl
viabil
enzym
activ
addit
cytotox
test
substanc
respect
cell
monitor
microscop
examin
magnif
cell
cultur
alter
cell
morpholog
determin
limit
toxic
concentr
mdck
fig
fig
bgm
fig
hela
fig
cell
cultiv
growth
period
togeth
differ
dilut
rang
vv
test
substanc
solvent
control
co
least
day
respect
cell
cultur
media
without
test
compon
use
control
medium
control
plaquereduct
assay
pfu
cytopathogen
effect
cpe
immunoassay
elisa
antivir
activ
bioaron
c
measur
plaquereduct
assay
cooper
plaqu
form
unit
pfu
flua
flub
yamagat
beiy
para
rsv
hrv
analys
cytopathogen
effect
cpe
adeno
cell
monolay
infect
multipl
infect
moi
flua
flua
flub
yamagat
flub
beiy
para
rsv
hrv
adeno
h
cell
monolay
wash
overlaid
agaros
final
concentr
contain
differ
concentr
test
substanc
subsequ
infect
cell
cultur
cultiv
day
mdck
flua
flua
hela
hrv
bgm
day
mdck
flub
yamagat
day
mdck
flub
beiy
para
day
rsv
adeno
lesion
visibl
cell
monolay
plaqu
cpe
viru
infect
control
group
cultiv
medium
alon
point
cell
fix
paraformaldehyd
remain
cell
monolay
stain
crystal
violet
solut
nonstain
lesion
cell
monolay
plaqu
cpe
quantifi
employ
optic
evalu
system
aid
diagnostika
gmbh
case
adeno
addit
analysi
cpe
amount
newli
synthesis
viru
determin
virusspecif
enzymelink
immunosorb
assay
elisa
merlin
diagnostika
gmbh
bornheimhersel
germani
quantif
antivir
activ
either
carri
analys
number
plaqu
pfu
flua
flub
para
hrv
rsv
lesion
viral
cpe
adeno
amount
viral
protein
detect
elisa
adeno
calcul
antivir
effect
base
mean
valu
four
cpe
adeno
pfu
beiy
six
pfu
flua
flub
para
hrv
rsv
replic
deriv
least
two
three
independ
experi
solvent
control
differ
cytotox
medium
control
includ
assay
result
nontreat
viru
control
group
defin
infect
inhibit
vitro
effect
test
substanc
standardis
rel
inhibitori
effect
determin
optim
concentr
substanc
assay
antivir
activ
cytotox
effect
test
substanc
solvent
control
onto
virussuscept
cell
mdck
hela
bgm
use
vitro
propag
virus
exclud
therefor
bioaron
c
solvent
control
test
vitro
cytotox
metabol
effect
onto
respect
cell
cultur
prepar
dilut
cell
cultur
medium
start
solut
determin
limit
toxic
concentr
respect
prepar
cell
cultiv
without
control
descend
concentr
log
test
substanc
solvent
control
rang
least
day
analys
cytotox
perform
mttassay
mosmann
addit
cytotox
test
substanc
respect
cell
monitor
microscop
examin
explain
result
analys
present
tabl
fig
mttassay
demonstr
low
cytotox
plant
extract
onto
cell
line
inhibitori
concentr
aqueou
arborescen
extract
bioaron
c
defin
solut
less
bgm
cell
fig
mdck
cell
fig
hela
cell
fig
cell
fig
assay
show
measur
differ
time
point
minor
differ
fig
solvent
control
show
valu
exceed
mean
cytotox
could
detect
data
assay
cytotox
summaris
tabl
fig
follow
data
aqueou
bioaron
c
arborescen
dilut
solut
determin
antivir
activ
test
antivir
activ
bioaron
c
viru
replic
therapeut
protocol
cell
mdck
hela
bgm
infect
multipl
infect
moi
describ
one
hour
infect
cell
wash
bioaron
c
ad
semisolid
overlay
cell
cultur
start
solut
follow
five
log
dilut
step
final
dilut
step
thereaft
cell
cultiv
day
describ
section
materi
method
lesion
visibl
respect
cell
monolay
plaqu
cpe
virusinfect
control
group
cultiv
medium
alon
antivir
activ
bioaron
c
dilut
determin
pfu
plaquereduct
assay
cooper
cpe
therefor
cell
monolay
fix
paraformaldehyd
remain
cell
stain
crystal
violet
solut
nonstain
lesion
cell
monolay
plaqu
cpe
quantifi
employ
optic
evalu
system
elispot
reader
aid
diagnostika
gmbh
result
analys
present
fig
show
dosedepend
antivir
activ
bioaron
c
respect
virus
result
includ
valu
determin
inhibitori
concentr
correl
cytotox
well
valu
describ
effect
concentr
antivir
activ
addit
summaris
tabl
bioaron
c
use
togeth
hrv
hela
cell
fig
show
highest
dose
vv
solut
mean
three
independ
studi
studi
studi
studi
fig
inhibit
viru
replic
obviou
dosedepend
activ
result
reduct
viruscaus
plaqu
even
rang
bioaron
c
solut
concentr
rang
use
three
independ
studi
mean
studi
tabl
besid
antivir
effect
hrv
bioaron
c
test
anoth
member
picornavirida
nonenvelop
plu
strand
rna
viru
coxsackieviru
subtyp
bioaron
c
littl
bit
less
effect
cell
compar
hrv
infect
activ
still
result
mean
two
studi
studi
studi
fig
plaquereduct
highest
concentr
clear
dosedepend
reactiv
rang
two
differ
experi
tabl
besid
reactiv
bioaron
c
nonenvelop
rna
virus
interest
reactiv
rna
well
dna
virus
therefor
reactiv
bioaron
c
studi
para
rsv
virus
belong
envelop
rna
virus
paramyxovirida
famili
fig
b
respect
virus
bioaron
c
show
moder
antivir
activ
effect
para
highest
concentr
rang
three
independ
experi
fig
obvious
reduc
dilut
bioaron
c
solut
show
antivir
activ
therefor
could
estim
solut
tabl
less
pronounc
antivir
activ
could
demonstr
rsv
fig
two
independ
studi
highest
concentr
bioaron
c
show
weak
antivir
activ
rang
complet
lost
dilut
concentr
fig
valu
bioaron
c
rsv
could
estim
tabl
antivir
effect
bioaron
c
demonstr
nonenvelop
dna
viru
adeno
member
adenovirida
famili
fig
tabl
ribavirin
known
reactiv
rna
virus
use
posit
control
includ
assay
final
concentr
could
confirm
antivir
activ
inhibit
hrv
replic
inhibit
inhibit
para
rsv
replic
data
shown
besid
virus
less
sensit
bioaron
c
treatment
anoth
group
virus
interest
influenza
virus
influenza
virus
envelop
rna
virus
belong
orthomyxovirida
detect
antivir
activ
bioaron
c
orthomyxovirida
four
differ
member
chosen
two
member
belong
genu
influenza
virus
influenza
flua
flua
addit
two
member
belong
genu
influenza
b
virus
flub
yamagat
flub
beiy
follow
assay
bioaron
c
show
outstand
dosedepend
reactiv
member
orthomyxovirida
fig
replic
flua
mdck
cell
nearli
complet
block
highest
solut
rang
three
independ
experi
studi
studi
studi
inhibit
mean
valu
fig
dosedepend
antivir
activ
result
valu
mean
valu
tabl
amantadin
includ
posit
control
final
concentr
confirm
antivir
activ
inhibit
flua
replic
even
efficaci
effect
bioaron
c
flua
suppress
mean
valu
three
independ
experi
fig
compar
effect
ribavirin
show
concentr
nearli
inhibit
antivir
effect
flu
dosedepend
solut
still
gave
reduct
fig
valu
could
locat
mean
valu
tabl
compar
flua
slightli
decreas
antivir
activ
bioaron
c
observ
member
flub
genu
regard
flub
yamagat
reduct
studi
visibl
highest
solut
bioaron
c
fig
mean
valu
antivir
effect
declin
rapidli
valu
rang
mean
valu
tabl
efficaci
reactiv
flub
beiy
determin
two
studi
studi
inhibit
studi
mean
valu
fig
valu
rang
tabl
posit
control
flub
viru
strain
serv
ribavirin
demonstr
concentr
nearli
strain
yamagat
inhibit
strain
beiy
fig
antivir
activ
bioaron
c
flua
plate
authent
plaqu
reduct
assay
present
mdck
cell
infect
flua
incub
day
agaros
overlay
contain
differ
dilut
bioaron
c
solvent
control
nontreat
viru
control
posit
control
ribavirin
includ
test
day
incub
period
cell
fix
stain
crystalviolet
plate
analys
elispot
analys
system
aid
diagnostika
gmbh
number
plaqu
indic
lower
left
corner
respect
well
correspond
studi
studi
studi
yamagat
studi
beiy
grey
highlight
tabl
respect
treatment
scenario
present
authent
plate
use
analys
respect
taken
togeth
data
clearli
demonstr
strong
antivir
activ
bioaron
c
member
orthomyxovirida
famili
test
data
also
indic
signific
activ
bioaron
c
member
famili
well
influenza
virus
precis
proven
experi
taken
togeth
result
vitro
test
antivir
activ
bioaron
c
variou
virus
respons
infect
upper
respiratori
tract
demonstr
clear
select
activ
nonenvelop
rna
virus
belong
picornavirida
envelop
rna
virus
belong
orthomyxovirida
interestingli
reduc
reactiv
visibl
member
paramyxovirida
repres
also
envelop
rna
virus
close
relat
orthomyxovirida
somehow
unexpect
antivir
extract
analys
far
show
similar
activ
two
viru
famili
shown
extract
e
senticosu
et
al
p
sidoid
micha
et
al
composit
differ
plant
extract
deriv
gentian
root
primula
flower
elder
flower
sorrel
herb
verbena
herb
et
al
activ
substanc
bioaron
c
aqueou
extract
arborecen
therefor
uniqu
orthomyxovirusspecif
reactiv
result
might
give
hint
possibl
mode
action
date
one
specul
test
includ
studi
infect
kinet
analys
member
respect
viru
famili
need
final
reason
lack
reactiv
dna
virus
seem
also
interest
might
indic
common
attribut
rna
virus
differ
dna
one
date
result
base
experi
one
nonenvelop
dna
viru
adenoviru
type
confirm
trial
dna
virus
interest
bioaron
c
research
might
check
potenti
activ
herp
virus
describ
plantderiv
extract
eg
extract
black
tea
contain
theaflavin
cantator
et
al
theaflavin
show
clear
reactiv
herpessimplex
type
viru
extract
deriv
origanum
vulgar
l
demonstr
activ
rsv
coxsacki
viru
analys
outstand
efficaci
bioaron
c
influenza
virus
may
conclud
major
gap
antivir
treatment
cover
research
far
two
class
synthet
antiinfluenza
drug
describ
inhibitor
ion
channel
eg
amantadin
rimantadin
neuraminidas
inhibitor
eg
osteltamivir
zanamivir
sinc
increas
resist
drug
report
clinic
efficaci
neuraminidas
inhibitor
serious
question
recent
cochran
review
jefferson
et
al
also
discuss
leibovici
paul
urgent
need
introduc
addit
reliabl
antiinfluenzaviru
agent
et
al
describ
plant
extract
deriv
thuja
orientali
franco
cuppresacea
aster
spathulifoliu
maxim
asteracea
pinu
thunbergii
parl
pinacea
antivir
activ
influenza
virus
vitro
characteris
extract
extract
ribe
nigrum
l
grossulariacea
leav
describ
recent
ehrhardt
et
al
high
antiinfluenza
potenti
seem
interfer
viru
internalis
regard
function
mechan
bioaron
c
specul
deal
similar
antivir
mechan
rajasekaaran
et
al
made
impress
studi
extract
plant
tropic
rain
forest
borneo
author
abl
identifi
eleven
crude
extract
inhibit
enzymat
activ
viral
neuraminidas
four
also
abl
show
inhibit
haemagglutin
extract
investig
standardis
purifi
howev
studi
well
studi
describ
repres
first
step
characteris
plant
extract
well
provid
substanti
support
use
plantderiv
substanc
novel
antiinfluenza
drug
candid
develop
seem
quit
possibl
alreadi
plantderiv
substanc
eg
polyphenol
eg
resveratrol
epigallocatechin
gallat
characteris
molecular
level
also
show
signific
antivir
activ
influenza
vitro
andor
vivo
especi
isoquercetin
influenc
vivo
mous
model
viru
replic
interestingli
vitro
synergist
effect
togeth
amantadin
determin
kim
et
al
compar
test
substanc
bioaron
c
show
regard
low
cytotox
big
differ
ic
ec
valu
interest
reactiv
pattern
noth
known
date
activ
substanc
respons
effect
fraction
extract
identif
activ
compon
might
appropri
approach
futur
research
anoth
target
futur
research
might
determin
alo
constitu
strong
affin
highli
specif
virusderiv
target
molecul
describ
eg
strong
viral
proteas
inhibitor
chrysin
found
mani
plant
wanget
al
final
bioaron
c
show
obviou
resound
vitro
efficaci
accord
indic
known
therapeut
effect
discov
underli
antivir
mechan
influenza
virus
remain
subject
futur
research
